Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec 12;3(1):12-19.
doi: 10.1007/s12177-009-9044-4.

Ocular disease in patients with ANCA-positive vasculitis

Ocular disease in patients with ANCA-positive vasculitis

Angela S Watkins et al. J Ocul Biol Dis Infor. .

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis-the term recently applied to Wegener's granulomatosis-is a rare multi-system inflammation characterized by necrotizing granulomas and vasculitis. We investigated the ocular manifestations of this disease in a group of patients drawn from five inflammatory eye disease clinics across the United States. Of 8,562 persons with ocular inflammation, 59 individuals were diagnosed with ANCA-positive vasculitis; 35 males and 21 females, aged 16 to 96 years, were included in this study. Ocular diagnoses were scleritis (75.0%), uveitis (17.9%), and other ocular inflammatory conditions (33.9%) including peripheral ulcerative keratitis and orbital pseudotumor. Mean duration of ocular disease was 4.6 years. Oral corticosteroids and other systemic immunosuppressive agents were used by 85.7% and 78.5% of patients, respectively. Over time, patients with ANCA-positive vasculitis experienced 2.75-fold higher mortality than other patients with inflammatory eye disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier survival plot demonstrating probability of survival over time for 7,957 SITE cohort patients who were managed on or before December 2005, and who were residents of the United States. Patients with ANCA-positive vasculitis (n = 56) are represented by the dashed line. Patients with all other diagnoses (n = 7,901) are represented by the solid line

References

    1. Lefrak SS, Matteson EL. Freidrich Wegener: the past and present. Chest. 2007;132(6):2065. doi: 10.1378/chest.07-2353. - DOI - PubMed
    1. Harman LE, Margo CE. Wegener's granulomatosis. Surv Ophthalmol. 1998;42(5):458–480. doi: 10.1016/S0039-6257(97)00133-1. - DOI - PubMed
    1. Sarraf P, Sneller MC. Pathogenesis of Wegener's granulomatosis: current concepts. Expert Rev Mol Med. 2005;7(8):1–19. doi: 10.1017/S146239940500921X. - DOI - PubMed
    1. Cotch MF, Hoffman GS, Yerg DE, et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum. 1996;39(1):87–92. doi: 10.1002/art.1780390112. - DOI - PubMed
    1. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–498. - PubMed

LinkOut - more resources